Pharming Group N.V. (PHAR)
| Market Cap | 858.69M -6.9% |
| Revenue (ttm) | 386.75M +6.8% |
| Net Income | 24.18M +6,230.1% |
| EPS | 0.28 +13,053.7% |
| Shares Out | 684.01M |
| PE Ratio | 43.59 |
| Forward PE | 28.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,025 |
| Open | 11.85 |
| Previous Close | 11.87 |
| Day's Range | 11.85 - 12.28 |
| 52-Week Range | 9.11 - 21.34 |
| Beta | 0.07 |
| Analysts | Strong Buy |
| Price Target | 35.10 (+186.3%) |
| Earnings Date | Oct 27, 2026 |
About PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price target is $35.1, which is an increase of 186.30% from the latest price.
News
Pharming (PHAR) Q3 2026 Earnings Call Transcript
Revenue grew 21% year-over-year as RUCONEST stabilized and Joenja expanded internationally.
Pharming Group Q3 Earnings Call Highlights
Pharming Group NASDAQ: PHAR reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated p...
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Pharming Group N.V. reported its third quarter 2026 financial results, with total revenues increasing by 21% to US$117.6 million, compared to US$97.3 million in the third quarter of 2025. RUCONEST rev...
Pharming Group Earnings Call Transcript: Q3 2026
Q3 revenue grew 21% and operating profit rose 89%, with RUCONEST returning to growth and Joenja expanding across markets. FY guidance was tightened, while pediatric launches and pipeline readouts provide further growth opportunities.
Pharming Group Earnings release: Q3 2026
Pharming Group released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Pharming Group Slides: Q3 2026
Pharming Group has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Pharming reports Q3 EPS 3c, consensus 7c
Reports Q3 revenue $117.6M, consensus $107.34M. Interim Co-Chief Executive Officer Kenneth Lynard commented: “This was a quarter of execution and delivery for Pharming (PHAR). We set three near-term g...
Pharming Q3 Revenue Jumps 21%, CVID Data Due In November
(RTTNews) - Pharming Group (PHAR) reported third quarter 2026 financial results, with double-digit revenue growth and higher profitability driven by continued demand for its rare disease therapies RUC...
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to...
Pharming narrows FY26 revenue view to $380M-$390M from $375M-$395M
Consensus $383.35M. Cuts FY26 operating expense view to $310M-$315M from $315M-$320M. The company said, “At ESID 2026, Pharming (PHAR) presented positive Phase II data for leniolisib in patients with ...
Pharming Group Q3 Prel. Revenue Rises; Tightens FY26 Revenue Guidance
(RTTNews) - Pharming Group N.V. (PHGUF.PK, PHGUF.OB, PHAR, PHARM.AS), a Netherlands-based biotechnology company focused on rare immune and genetic diseases, on Thursday reported increased preliminary ...
Pharming Group announces third quarter 2026 revenues above market expectations
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in lin...
Pharming Group Earnings release: Q3 2026
Pharming Group released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Pharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders
(RTTNews) - Pharming Group N.V. (PHAR) reported positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies associated wit...
Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders
(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies...
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerate...
Pharming announces CEO Fabrice Chouraqui to step down
Pharming (PHAR) announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Chouraqui will step down as CEO and Executive Director, with immediate effect. To ensure continuit...
Pharming announces CEO transition
Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Bo...
Pharming announces FDA acceptance, Priority review of sNDA for Joenja
Pharming (PHAR) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application seeking approval for lower doses of Joenja, an oral, selective phosphoinositide ...
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with AP...
Pharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright
Initial Phase 2 data for Pharming’s (PHAR) Leniolisib in genetically defined PIDs beyond APDS are encouraging, showing improvements in lymphoproliferative measures without new safety signals, with add...
Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
Pharming (PHAR) announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies with immune dy...
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report...
Pharming Group Slides: Investor presentation
Pharming Group has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are e...